Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Is Plunging Today

By Prosper Junior Bakiny – Updated Jun 3, 2020 at 3:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the country’s top COVID-19 experts made some discouraging comments regarding a potential vaccine for the coronavirus.

What happened?

Shares of Novavax (NVAX 4.30%) are down by 13.2% as of 2:58 p.m. EDT on Wednesday, despite the company not reporting any news. However, it seems likely that the market is reacting to the comments made yesterday by Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), regarding the "durability" of a potential vaccine for the novel coronavirus. 

So what

Novavax has been one of the leaders in the race to develop a vaccine for COVID-19. The company recently announced the initiation of a phase 1/2 clinical trial to investigate the efficacy of its potential vaccine for COVID-19 -- NVX-CoV2373. The phase 1 part of this trial, to be conducted in Australia, will enroll 130 healthy adult volunteers and will test the vaccine's safety and its immunogenicity.

Preliminary results from the phase 1 part are expected in July. The phase 2 part of the trial will be held in the U.S. and several other countries. It will test the vaccine's safety, its ability to enhance immune responses, and its disease-reduction capabilities in a wider pool of participants.

Man standing in front of a board holding his head, looking at at downward pointing graph.

Image Source: Getty Images.

Investors have high hopes for Novavax's NVX-CoV2373, but Dr. Anthony Fauci gave us all a reality check when he said the following in an interview with JAMA editor Howard Bauchner:

When you look at the history of coronaviruses, the common coronaviruses that cause the common cold, the reports in the literature are that the durability of immunity that's protective ranges from three to six months to almost always less than a year.

In short, Dr. Fauci believes a potential vaccine for COVID-19 "may not provide long-term immunity."

Now what

Even with today's drop, shares of Novavax are up by a whopping 995% since the year started. But investors should remember that this biotech stock will continue to be volatile, and if Novavax loses the race to market a vaccine for COVID-19, its shares will probably implode. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$19.40 (4.30%) $0.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.